The federal government has a specific legal process to move drugs between legal categories. Even if the FDA (the drug-approving agency) recommends psilocybin for rescheduling, the DEA (the drug-enforcement agency) must wait 60+ days for public comments, coordinate with other agencies, and publish a final decision. This takes 2–3 years minimum. Since the FDA hasn't made a recommendation yet, you're looking at 2029 earliest.
DEA rescheduling under the CSA requires: FDA recommendation, DEA initiation, mandatory public comment (minimum 60 days), interagency coordination with HHS and DOJ, and final rule publication. Historical precedent (cannabis, MDMA reviews) shows this process takes 24–36+ months from FDA action. No FDA recommendation for psilocybin rescheduling has been issued as of May 2026. The procedural floor alone makes sub-2029 rescheduling implausible absent emergency executive action, which has no current signal.